Related Experiment Video
Updated: Jul 4, 2025

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape
Giorgia Scafetta1, Calogero D'Alessandria2, Armando Bartolazzi3,4
1Pathology Research Laboratory St, Andrea University Hospital, Via Di Grottarossa 1035, 00189, Rome, Italy.
Abstract:
Immunotherapy with checkpoint inhibitors (ICIs) has radically changed the landscape of therapeutic opportunities in oncology, but much still needs to be understood from a mechanistic point of view. There is space for further improving tumors' response to ICIs, as supported by a strong biological rationale. For this achievement a detailed analysis of tumor cell phenotype with functional dissection of the molecular interactions occurring in the TME is required. Galectin-3 is a pleiotropic tumor relevant molecule, which deserves particular attention in immuno-oncology. Due to its ability to finely modulate immune response in vivo, Galectin-3 is a potential target molecule to be considered for overcoming tumor immune escape.
Related Concept Videos
Tumor Immunotherapy
Selectins
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

